Merck & Company Inc (MRK)

86.51
+4.97(+6.10%)
  • Volume:
    17,741,537
  • Bid/Ask:
    86.50/86.51
  • Day's Range:
    83.17 - 86.54

MRK Overview

Prev. Close
81.54
Day's Range
83.17-86.54
Revenue
47.1B
Open
83.52
52 wk Range
68.38-86.54
EPS
1.89
Volume
17,741,537
Market Cap
206.41B
Dividend (Yield)
2.60
(3.16%)
Average Volume (3m)
13,405,202
P/E Ratio
43.16
Beta
0.43
1-Year Change
9.65%
Shares Outstanding
2,531,374,696
Next Earnings Date
27 Oct 2021
What is your sentiment on Merck & Company Inc?
or
Vote to see community's results!

Merck & Company Inc News

Merck & Company Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Merck & Company Inc Company Profile

Merck & Company Inc Company Profile

Employees
73500

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Read More
  • Just started. More to go!
    0
    • it is going up
      0
      • What happen to MRK ? Time to buy ?
        0
        • it will cross 81 in coming days
          1
          • The immuno-oncology drugs are promising, but $81.65 seems a bit over-excited. It's no cure, just prolonging life a small amount in end-stage patients who were resistant to normal treatments. A pullback to $70 on the cards in the next 6months would be realistic.
            2
            • nice input
              0
            • nice input
              0
          • It will be going up
            0
            • Position buy will be up price
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.